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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not oral 
rivaroxaban is safe and effective in the treatment of patients with symptomatic DVT.  
STUDY DESIGN: Review of three English language primary randomized controlled trial studies 
published from 2007-2011. 
DATA SOURCES: Three randomized controlled trials studying the effectiveness and safety of 
rivaroxaban in the treatment of patients with symptomatic DVT in comparison to enoxaparin and 
placebo.  
OUTCOMES MEASURED: Outcomes measured were episodes of recurrent DVT and bleeding. 
Patients were monitored for the proposed treatment period and seen at fixed intervals that were 
matching for the rivaroxaban and comparison groups. At this time a checklist was used to gather 
information on symptoms and signs of recurrent venous thromboembolism, bleeding, and 
adverse events. 
RESULTS: The articles showed rivaroxaban is safe and effective in the treatment of patients 
with deep venous thrombosis. The primary efficacy outcome in all was episodes of recurrent 
DVT. The principle safety outcome in all studies was clinically relevant major and non-major 
bleeding. 
CONCLUSIONS: This review supports the use of rivaroxaban in the treatment of patients with 
symptomatic deep venous thrombosis. More information is needed for the use of the drug in 
special populations such as cancer patients.  
KEY WORDS: Rivaroxaban, Treatment, DVT  
 
 
 
 
 
 
 
 
INTRODUCTION  
Deep venous thrombosis (DVT) is a blood clot that most commonly forms in the deep 
veins of the arms or legs and may lead to emboli.  A clot forms when something slows or causes 
an alteration in blood flow such as hospitalization. This paper evaluates three randomized, 
controlled trials (double blind, parallel group phase II, open label) in the safety and effectiveness 
of rivaroxaban in the treatment of patients with symptomatic DVT. The precise number of 
people affected by DVT is unknown, but estimates range from 300,000 to 600,000 (1 to 2 per 
1,000, and in those over 80 years of age, 1 in 100) each year in the US.4 33% of people with 
DVT will have a recurrence within 10 years.4 The total annual healthcare cost for a Venous 
Thromboembolism (VTE) ranged from $7594 to $16,644, depending on the type of event and 
whether it was a primary or secondary diagnosis.5 The recurrent DVT event was associated with 
21% greater cost compared with the initial DVT event.5 DVT was diagnosed in an estimated 
annual average of 348,558 hospitalizations.6 
Various factors can lead to DVT such as age, obesity, smoking, heart failure, oral 
contraception, venous stasis due to immobilization, cancer, stroke, pregnancy, polycythemia 
vera, factor deficiencies, etc. Among people who have had a DVT, 50% will have long-term 
symptoms such as swelling, pain, discoloration, and scaling in the affected limb.4 Numerous 
methods are used to treat the condition including unfractionated or low molecular weight 
heparin, vitamin K antagonists, selective factor Xa inhibitors, direct thrombin inhibitor, inferior 
vena cava filters, and fibrinolytic therapy. Current treatments of DVT have limitations due to the 
required laboratory monitoring for dose initiation and adjustment, narrow therapeutic window, 
and are subject to food and drug interactions.2 Rivaroxaban is being proposed as an alternative in 
treatment because it does not need laboratory monitoring, has a wide therapeutic window, is safe 
in long term use, and has oral route of administration.3 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not oral 
rivaroxaban is safe and effective in the treatment of patients with symptomatic DVT. 
METHODS 
 Articles designated for this selective evidence based medicine (EBM) review have met 
precise requirements to explore the objective. The articles consisted of three randomized control 
trials. The articles were selected using the key words: rivaroxaban, treatment, and DVT. The 
author of this selective EBM review conducted the research in PubMed, Cochrane, and OVID. 
All articles were published in the English language in peer-reviewed journals. Articles were 
chosen if they targeted patients with DVT, included patient oriented outcomes, and population 
age greater than 18. Articles were excluded if they were systematic reviews, non- patient 
oriented outcomes, and population age less than 18. Statistics were reported using p-values, 95% 
confidence intervals (CI), relative risk reduction (RRR), absolute risk reduction (ARR), relative 
risk increase (RRI), absolute risk increase (ARI), number needed to treat (NNT), and number 
needed to harm (NNH). 
 In the Einstein’s study which was an open label, randomized, event driven, non-
inferiority study  patients were assigned to receive oral rivaroxaban 15mg twice daily for the first 
three weeks, followed by 20mg once daily for the anticipated 3, 6, or 12 months of treatment.1 In 
Agnelli’s group phase II trial study the oral rivaroxaban group received doubled blinded doses of 
10, 20, or 30mg twice daily or 40mg once daily, with food for 12 weeks.2 In both studies patients 
in the standard anticoagulant group received subcutaneous enoxaparin 1mg/kg twice daily 
followed by vitamin K antagonist such as warfarin. In Roumaldi’s double blind, placebo 
controlled superiority study, patients were assigned to receive rivaroxaban 20mg or placebo for 
6-12 months.3 Outcomes measured include incidence of recurrent DVT and bleeding. The 
demographics of the studies included are demonstrated in Table 1.  
OUTCOMES MEASURED  
 The primary efficacy outcomes of the studies was the incidence of symptomatic recurrent 
VTE, defined as a composite of DVT and pulmonary embolism.3 The safety outcome measured 
in all the studies is bleeding. Bleeding was considered major if it was fatal, affected a critical 
organ, led to treatment cessation, or transfusion of two or more units of packed red blood cells or 
whole blood.2 Patients were monitored for the proposed treatment period and seen at fixed 
intervals that were matching for the rivaroxaban and comparison groups. At this time a checklist 
was used to gather information on symptoms and signs of recurrent venous thromboembolism, 
bleeding, and adverse events.  
RESULTS 
Three randomized control trials evaluated in this review include a parallel group phase II 
trial, an open label event driven, noninferiority study and a double blind, event driven superiority 
study. Two of the studies compared rivaroxaban to enoxaparin plus vitamin K antagonist while 
one compared rivaroxaban to placebo. Patients included in the studies were all of legal age for 
consent and had symptomatic DVT. The primary efficacy outcome in all studies was episodes of 
recurrent DVT. The principle safety outcome in all studies was clinically relevant major and 
non-major bleeding. The principle safety outcome was measured via events such as treatment  
Table 1: Demographics and Characteristics of included studies  
Study  Type # pts  Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Intervention  
Einstein1,  
2010  
RCT 
Open label, 
randomized, 
even driven, 
noninferiority 
study 
3449 18 
years 
or 
older  
-legal age 
of consent  
-confirmed 
DVT 
-no 
symptoms 
of PE  
-Pts with heparin, 
VKA treatment for 
>48 hrs, treatment 
with 
thromboectomy, 
vena cava filter, or 
fibrinolytic agent, 
liver disease, 
active bleeding, 
BP>180/110, 
pregnancy, 
CrCl<30ml/min, 
bacterial 
endocarditis, life 
expectancy<3mos 
66 -regimen of 
15 mg bid or 
20mg QD 
PO 
rivaroxaban  
-1.0 mg/kg 
of body 
weight bid 
subQ 
enoxaparin 
+ VKA 
Agnelli2, 
2007 
RCT 
parallel-
group phase 
II trial 
636 18 
years 
or 
older 
-age 18+ 
-no 
symptoms 
of PE  
-not 
received 
VKA 
-no more 
than 36 hrs 
of 
treatment 
with 
LMWH 
-cerebral ischemia, 
intracerebral 
bleeding or GI 
bleeding within 
past 6 months, 
surgery within past 
4 weeks, active 
PUD, known 
bleeding disorder, 
prolonged INR, 
platelet count 
<100X10^9/L, 
body wt <45kg, 
uncontrolled HTN, 
heart failure, 
CrCl<30ml/min, 
pregnancy 
32 -rivaroxaban 
10, 20, or 30 
mg BID or 
40mg once 
daily 
-enoxaparin 
1 mg/kg 
BID 
followed by 
vitamin K 
antagonist 
Romualdi3 
2011  
 
RCT  
double blind, 
placebo 
controlled 
superiority 
study 
1197 Mean 
age 
58 
years  
-Patients 
with 
confirmed 
DVT  
-indication for 
VKA, renal 
insufficiency, liver 
disease, bacterial 
endocarditis, 
active bleeding or 
high risk of 
bleeding, 
uncontrolled HTN, 
pregnancy  
N/A -rivaroxaban 
20mg once 
daily 
cessation and blood transfusions. The primary efficacy outcome was measured via checklist used 
to identify signs and symptoms of recurrent DVT.  
This review also looked at safety outcomes measured by percentage of treatment 
emergent adverse events. The percentages reported were used to calculate Relative Risk Increase 
(RRI) and Absolute Risk Increase (ARI). The ARI value is used to calculate the Numbers 
Needed to Harm (NNH). The NNH tells the clinician how many patients can be treated with the 
experimental treatment over the control treatment before one patient will be harmed. 
Einstein’s 2010 study consisted of 3449 patients in whom 1731 were given rivaroxaban 
while 1718 were given enoxaparin plus vitamin K antagonist. Patients were assigned to receive 
oral rivaroxaban 15mg twice daily for the first three weeks, followed by 20mg once daily for the 
anticipated 3, 6, or 12 months of treatment.1 Patients who received standard therapy received 
subcutaneous enoxaparin 1.0 mg/kg, and either warfarin or acenocoumarol. Patients were 
followed for the treatment duration and seen at fixed intervals that were identical for 
experimental and comparison groups, at which time a checklist was used to elicit information on 
symptoms and signs of recurrent VTE, bleeding, and adverse events.1 Adverse events leading to 
discontinuation of study drug occurred in 4.9% of patients receiving rivaroxaban and 4.7% of 
patients in the control group. Recurrent DVT occurred in 14 patients of the rivaroxaban group 
compared to 28 patients receiving enoxaparin plus vitamin K antagonist. The primary efficacy 
outcome occurred in 2.1% of patients in the rivaroxaban group and in 3% of patients in the 
standard therapy group causing a hazard ratio of .68 and 95% CI of .44-1.04. The principal safety 
outcome occurred in 139 patients in the rivaroxaban group and 138 patients receiving standard 
therapy. The hazard ratio was .97 and 95% CI was .76 to 1.22. 196 patients in the rovaroxaban 
discontinued treatment due to adverse events, consent withdrawn or lost to follow up. The NNH 
value was 0 indicating no difference in  major bleeding rates between the experimental and 
control groups. The NNT value was -111 indicating for every 111th person treated with 
rivaroxaban, DVT occurred in one less person. These results are summarized in tables 2 and 3.  
Table 2: Adverse Event Data for Rivaroxaban  
HARM CER 
(enoxaparin/VKA) 
EER 
(rivaroxaban) 
RRI ARI NNH CI P-value 
Einstein, 
2010 
.081 .081  0 0 .76-1.22 .77 
 
Table 3: Efficacy of Rivaroxaban in the Prevention of DVT  
Prevention CER 
(enoxaparin/VKA) 
EER 
(rivaroxaban) 
RRR ARR NNT CI P-value 
Einstein, 
2010 
.03 .021 -.30 -.009 -111 .44-
1.04 
<.001 
 
In Roumaldi’s 2011 study, 1197 patients were enrolled in the study. 34.1% completed the 
DVT study, 19.1% completed the PE study and 47.5% came from routine care.3 The average age 
of patients was 58 years. The primary efficacy outcome occurred in 8 out of 602 patients in the 
rivaroxaban group and 42 out of 594 patients in the placebo group for a hazard ratio of .18, 95% 
CI of .09-.39and P-value<.001.3 Major bleeding occurred in 4 patients receiving rivaroxaban 
with no episodes in patients receiving placebo. The net clinical benefit defined as the composite 
of primary efficacy outcome and major bleeding, occurred in 12 patients receiving rivaroxaban 
and in 42 patients receiving placebo, for a hazard ratio of .28 and 95% confidence interval of .15-
.53. 76 patients in the rivaroxaban group discontinued treatment due to adverse events, 
withdrawn consent or lost to follow up.  Non-major bleeding which consisted of mucosal 
bleeding was increased from 1.2% in placebo group to 5.4% in those treated with rivaroxaban. 
However patients continued treatment and overall benefits outweighed risks. The NNH value 
was 143, which means for every 143 patients one more patient would have an episode of major 
bleeding with rivaroxaban than with control after a period of time of 6 months. The NNT value 
was  -17 meaning for every 17th  patient treated with rivaroxaban DVT occurred in one less 
person with a 95% CI of .09-.39 and p-value<.001. These values are summarized in tables 4 and 
5.  
Table 4: Adverse Event Data for Rivaroxaban  
HARM CER (placebo) EER 
(rivaroxaban) 
RRI ARI NNH CI P-value 
Roumaldi, 
2011 
0 .007  .007 143  .11 
 
Table 5: Efficacy of Rivaroxaban in the Prevention of DV T 
Prevention CER (placebo) EER 
(rivaroxaban) 
RRR ARR NNT Ci P-value 
Roumaldi, 
2011 
.071 .013 -.82 -.058 -17 .09-.39 <.001 
 
In Agnelli’s 2007 study 636 patients were enrolled in the study. 613 patients were 
randomized while 23 could not be randomized due to violation of protocol. An additional 9 
patients did not receive treatment due to protocol violation or withdrawn consent leaving 602 
patients who received study drug. Patients in the rivaroxaban were split up to receive either 10, 
20, 30 milligrams twice daily or 40 milligrams once daily of rivaroxaban compared with 
enoxaparin 1 mg/kg twice daily followed by vitamin K antagonist. Patients received treatment 
for 12 weeks. The primary safety endpoint was major bleeding. Bleeding was considered major 
if it was fatal, affected a critical organ, led to treatment cessation, or transfusion of two or more 
units of blood.2 Major bleeding was observed in 1.7%, 1.7%, 3.3%, and 1.7% of patients 
receiving rivaroxaban 10, 20, 30, milligrams twice daily or 40 milligrams once daily 
respectively.2 No episodes of major bleeding occurred in the enoxaparin group. A total of 18 
patients discontinued treatment due to protocol violation or lack of compliance. Table 6 
summarizes incidence of major and non-major bleeding. The NNH value was 59 meaning for 
every 59 patients one more patient would have an episode of major bleeding with rivaroxaban 
than with control for a period of time of 12 weeks and a p-value of .39. These results are 
summarized in table 7. 
Table 6: Incidence of Adverse Events  
 Rivaroxaban Enoxaparin/VKA 
 10mg bid 
(n=119) 
20mg BID 
(n=117) 
30mg BID 
(n=121) 
40mg QD 
(n=121) 
N=126 
Any bleeding 6 (5%) 11 (9.4%) 13 (10.7%) 14 (11.6%) 8 (6.3%) 
Major 
bleeding 
2 (1.7%) 2 (1.7%) 4 (3.3%) 2 (1.7%) 0 
Bleeding 
leading to 
transfusion 
2 (1.7%) 0 2 (1.7%) 1 (.8%) 0 
Bleeding 
warranting 
treatment 
cessation 
1 (.8%) 2 (1.7%) 3 (2.5%) 1 (.8%) 0 
Minor 
bleeding 
4 (3.4%) 9 (7.7%) 11 (9.1%) 12 (9.9%) 8 (6.3%) 
95% CI .2-5.9 .2-.6 .9-8.3 .2-5.8 .0-2.9 
 
Table 7: Adverse Event Data for Rivaroxaban  
HARM CER 
(enoxaparin/VKA) 
EER 
(rivaroxaban) 
RRI ARI NNH CI P-value 
Agnelli, 
2007 
0 .017  .017 59 varied .39 
 
DISCUSSION 
Rivaroxaban, a factor Xa inhibitor provides an advantage over other therapies due to its 
oral route of administration, single drug approach, and does not require laboratory monitoring. 
This provides advantages for physicians and patients, along with improving compliances. 
Rivaroxaban is also a cost effective drug.  
One of the most common uses of rivaroxaban includes DVT prophylaxis for patients 
receiving hip or knee replacement surgery. Other indications of its use include pulmonary 
embolism prophylaxis, atrial fibrillation and non-valvular cerebrovascular accident. 
Contraindications to using rivaroxaban consist of active bleeding and hypersensitivity reaction to 
the drug. There is insufficient evidence in relation to its use in pregnancy and is a category C 
drug. The black box warning states that stopping rivaroxaban increases a patient’s risk of 
thrombotic events such as stroke. Patients receiving neuraxial anesthesia or undergoing spinal 
puncture and are using rivaroxaban can get epidural or spinal hematomas, which may result in 
long term or everlasting paralysis. Aspirin, non-steroidal anti-inflammatory drugs, heparin, and 
warfarin are amongst drugs that can cause increased risk of bleeding if taken with rivaroxaban.  
The use of newer drugs may change the way anticoagulation clinics currently work. For 
example the measurement of alternative blood tests such as D-dimer, ultrasound testing and 
immediate availability in case of signs and symptoms or recurrence, bleeding, or other clinical 
problems can be important.3  
One limitation of Agnelli’s study is that study populations were younger, and few had 
active cancer, which may have reduced the likelihood of thrombus extension or bleeding events.2 
The Einstein study had an open design which allowed potential for a diagnostic suspicion bias.1 
CONCLUSION 
Rivaroxaban provides a solo drug approach to the short term and continued treatment of 
venous thrombosis that may expand the benefits of anticoagulation. The studies presented in this 
review support the safety and efficacy of using rivaroxaban in the treatment of DVT. The large 
p-values for adverse events mean the prevention of bleeding may have occurred by chance or 
coincidence. Rivaroxaban provides alternative treatment to other regimens such as enoxaparin 
plus vitamin K antagonist. One of the major advantages of using rivaroxaban is that it does not 
require laboratory monitoring and has decreased food and drug interactions. Another advantage 
includes the drug’s oral route of administration.  
Future studies should focus on finding the most effective and safe dosages for the use of 
rivaroxaban. Dosages can be individualized to patients and also depend on other co-morbidities 
present. Another area of interest is to assess the safety of rivaroxaban in distinct populations 
including elderly, obese patients, patients with liver or renal impairment, and patients with 
cancer. These are amongst some of the populations that were poorly represented in these studies. 
Although DVT is less common in adolescents; the treatment of DVT with rivaroxaban in 
adolescents with DVT should also be incorporated in future studies.  
In conclusion, the factor Xa inhibitor rivaroxaban proves to be a safe and effective single 
drug approach in the treatment of patients with symptomatic deep vein thrombosis.  
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